ANGLE plc (ANPCF)
USD 0.16
(0.0%)
USD 0.16
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.18 Million GBP | 109.99% |
| 2022 | 1.04 Million GBP | 2.76% |
| 2021 | 1.01 Million GBP | 32.94% |
| 2020 | 762 Thousand GBP | -12.56% |
| 2019 | 871.5 Thousand GBP | 28.54% |
| 2018 | 678 Thousand GBP | 7.96% |
| 2017 | 628 Thousand GBP | 26.1% |
| 2016 | 498 Thousand GBP | 37.95% |
| 2015 | 361 Thousand GBP | 0.0% |
| 2014 | - GBP | -100.0% |
| 2013 | 801 Thousand GBP | -17.34% |
| 2012 | 969.02 Thousand GBP | -31.13% |
| 2011 | 1.4 Million GBP | -41.86% |
| 2010 | 2.42 Million GBP | -1.39% |
| 2009 | 2.45 Million GBP | -51.54% |
| 2008 | 5.06 Million GBP | 30.75% |
| 2007 | 3.87 Million GBP | 14.69% |
| 2006 | 3.37 Million GBP | -17.49% |
| 2005 | 4.09 Million GBP | 0.0% |
| 2004 | 4.09 Million GBP | 42.32% |
| 2003 | 2.87 Million GBP | 45.03% |
| 2002 | 1.98 Million GBP | 11.03% |
| 2001 | 1.78 Million GBP | 52.39% |
| 2000 | 1.17 Million GBP | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 517 Thousand GBP | 4.44% |
| 2024 Q2 | 517 Thousand GBP | 0.0% |
| 2023 Q1 | 598 Thousand GBP | -3.86% |
| 2023 Q3 | 495 Thousand GBP | -58.61% |
| 2023 Q4 | 495 Thousand GBP | 0.0% |
| 2023 FY | 2.18 Million GBP | 109.99% |
| 2023 Q2 | 1.19 Million GBP | 100.0% |
| 2022 Q4 | 622 Thousand GBP | 100.0% |
| 2022 Q2 | 419 Thousand GBP | 100.0% |
| 2022 Q1 | 209.5 Thousand GBP | -70.78% |
| 2022 FY | 1.04 Million GBP | 2.76% |
| 2022 Q3 | 311 Thousand GBP | -25.78% |
| 2021 Q1 | 148 Thousand GBP | -71.92% |
| 2021 Q4 | 717 Thousand GBP | 100.0% |
| 2021 Q2 | 296 Thousand GBP | 100.0% |
| 2021 FY | 1.01 Million GBP | 32.94% |
| 2021 Q3 | 358.5 Thousand GBP | 21.11% |
| 2020 Q2 | 235 Thousand GBP | 100.0% |
| 2020 Q1 | 117.5 Thousand GBP | 0.0% |
| 2020 FY | 762 Thousand GBP | -12.56% |
| 2020 Q3 | 263.5 Thousand GBP | 12.13% |
| 2020 Q4 | 527 Thousand GBP | 100.0% |
| 2019 Q1 | 202.5 Thousand GBP | 0.0% |
| 2019 FY | 871.5 Thousand GBP | 28.54% |
| 2019 Q2 | 192 Thousand GBP | -5.19% |
| 2018 Q3 | 273 Thousand GBP | 0.0% |
| 2018 Q1 | 440 Thousand GBP | 100.0% |
| 2018 Q4 | 202.5 Thousand GBP | -25.82% |
| 2018 FY | 678 Thousand GBP | 7.96% |
| 2017 Q2 | 94 Thousand GBP | 0.0% |
| 2017 Q4 | 220 Thousand GBP | 134.04% |
| 2017 Q3 | 94 Thousand GBP | 0.0% |
| 2017 FY | 628 Thousand GBP | 26.1% |
| 2016 Q1 | 180.5 Thousand GBP | 0.0% |
| 2016 Q3 | 109.5 Thousand GBP | 0.0% |
| 2016 Q2 | 109.5 Thousand GBP | -39.34% |
| 2016 FY | 498 Thousand GBP | 37.95% |
| 2015 FY | 361 Thousand GBP | 0.0% |
| 2015 Q1 | - GBP | 0.0% |
| 2015 Q2 | - GBP | 0.0% |
| 2015 Q3 | - GBP | 0.0% |
| 2015 Q4 | 180.5 Thousand GBP | 0.0% |
| 2014 Q1 | - GBP | -100.0% |
| 2014 Q4 | - GBP | 0.0% |
| 2014 Q3 | - GBP | 0.0% |
| 2014 FY | - GBP | -100.0% |
| 2014 Q2 | - GBP | 0.0% |
| 2013 Q2 | 409 Thousand GBP | 12.05% |
| 2013 Q3 | 409 Thousand GBP | 0.0% |
| 2013 FY | 801 Thousand GBP | -17.34% |
| 2013 Q1 | 365 Thousand GBP | 0.0% |
| 2013 Q4 | 658.5 Thousand GBP | 61.0% |
| 2012 Q4 | 365 Thousand GBP | -3.05% |
| 2012 FY | 969.02 Thousand GBP | -31.13% |
| 2012 Q2 | 376.5 Thousand GBP | 0.0% |
| 2012 Q3 | 376.5 Thousand GBP | 0.0% |
| 2011 FY | 1.4 Million GBP | -41.86% |
| 2010 FY | 2.42 Million GBP | -1.39% |
| 2009 FY | 2.45 Million GBP | -51.54% |
| 2008 FY | 5.06 Million GBP | 30.75% |
| 2007 FY | 3.87 Million GBP | 14.69% |
| 2006 FY | 3.37 Million GBP | -17.49% |
| 2005 FY | 4.09 Million GBP | 0.0% |
| 2004 FY | 4.09 Million GBP | 42.32% |
| 2003 FY | 2.87 Million GBP | 45.03% |
| 2002 FY | 1.98 Million GBP | 11.03% |
| 2001 FY | 1.78 Million GBP | 52.39% |
| 2000 FY | 1.17 Million GBP | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Bio Medica Corporation | 913 Thousand USD | -139.43% |
| Arrayit Corporation | 4.37 Million USD | 50.061% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 25.85 Million USD | 91.546% |
| Bioqual, Inc. | 58.59 Million USD | 96.269% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 15.29 Million USD | 85.709% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion USD | 99.97% |
| HTG Molecular Diagnostics, Inc. | 6.36 Million USD | 65.663% |
| iMD Companies, Inc. | - USD | -Infinity% |
| IDenta Corp. | 1.05 Million USD | -107.876% |
| Interpace Biosciences, Inc. | 40.21 Million USD | 94.564% |
| Integrative Health Technologies, Inc. | 447.49 Thousand USD | -388.493% |
| InVitro International | 792.62 Thousand USD | -175.791% |
| Lumos Diagnostics Holdings Limited | 11.13 Million USD | 80.361% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 7.22 Million USD | 69.741% |
| NovelStem International Corp. | 12 Thousand USD | -18116.667% |
| Optigenex Inc. | 465.97 Thousand USD | -369.129% |
| PharmChem, Inc. | 6.01 Million USD | 63.642% |
| Proteome Sciences plc | 6.4 Million USD | 65.847% |
| Response Genetics, Inc | 18.04 Million USD | 87.882% |
| Rennova Health, Inc. | 13.03 Million USD | 83.231% |
| RushNet, Inc. | 1.78 Million USD | -22.268% |
| ScreenPro Security Inc. | 1.91 Million USD | -14.205% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | 3.79 Million USD | 42.399% |
| Todos Medical Ltd. | 7.69 Million USD | 71.592% |